1. Antioxidant effects of a novel pioglitazone analogue (PA9) in a rat model of diabetes: Modulation of redox homeostasis and preservation of tissue architecture.
- Author
-
Shakour N, Mahdinezhad MR, Asgharzadeh F, Khazaei M, Simental-Mendía LE, Roshan NM, Sahebkar A, and Hadizadeh F
- Subjects
- Animals, Male, Rats, Rats, Wistar, Thiazolidinediones pharmacology, Thiazolidinediones therapeutic use, Pancreas drug effects, Pancreas pathology, Pancreas metabolism, Kidney drug effects, Kidney pathology, Kidney metabolism, Liver drug effects, Liver metabolism, Liver pathology, Catalase metabolism, Malondialdehyde metabolism, Superoxide Dismutase metabolism, Antioxidants pharmacology, Pioglitazone pharmacology, Pioglitazone therapeutic use, Homeostasis drug effects, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Experimental metabolism, Oxidation-Reduction drug effects, Oxidative Stress drug effects, Hypoglycemic Agents pharmacology, Hypoglycemic Agents therapeutic use
- Abstract
Oxygen-free radicals have been implicated in the initiation of diabetic complications. Thiazolidinediones (TZDs), known for their antidiabetic properties, also demonstrate notable antioxidant and anti-inflammatory effects. Although a recently developed imidazolyl analogue of pioglitazone (PA9) has exhibited superior glucose-lowering efficacy compared to pioglitazone, its antioxidant effects remain unexplored. Thus, the objective of this study is to evaluate the antioxidant properties of PA9 in animal models with diabetes. Rats were randomly separated into the following four groups: control, diabetic, and two groups treated orally with pioglitazone as a standard drug and PA9 for ten days. Upon completion of the experiment, tissues from the liver, heart, brain, pancreas, spleen, and kidneys were collected to assess oxidant/antioxidant markers and histological alterations. The administration of PA9 resulted in a noteworthy reduction in malondialdehyde (MDA) levels compared to the diabetic group (p < 0.05). The group receiving PA9 displayed elevated levels of three antioxidant markers, catalase (CAT), superoxide dismutase (SOD), and total thiol, in pancreatic tissue compared to diabetic rats (p < 0.05). Furthermore, increased content of CAT was evident in the heart (p < 0.05), spleen (p < 0.001), brain, and kidney tissues in the PA9-treated group, along with augmented thiol content in the spleen compared to the diabetic group. Remarkably, no significant histological changes were observed in the liver, pancreas, heart, brain, spleen, and kidneys of the PA9-treated groups relative to diabetic rats. PA9 effectively mitigates oxidative stress, modulates redox homeostasis, and shows promise in preventing diabetic complications. The proven safety profile of this analogue underscores its potential, warranting comprehensive clinical evaluation to thoroughly understand its therapeutic scope and efficacy in the management of diabetes., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF